From multi‐omics to precision medicine in intracranial aneurysm: Biomarker discovery and multimodal integration

Despite extensive research, currently, no biomarkers are available for clinical use in intracranial aneurysm (IA). However, recent advancements in high‐throughput technologies have opened new possibilities for understanding IA's complex pathophysiology. These technologies generate extensive datasets across multiple molecular domains, including genomics, transcriptomics, proteomics, metabolomics, and microbiomics. By integrating multi‐omics data, it is now possible to analyze thousands of genes, RNAs, proteins, metabolites, and microbiota simultaneously, revealing complex interaction networks across these molecular layers. This integrative approach offers significant insights into IA pathogenesis, helps identify potential therapeutic targets, and paves the way for discovering novel biomarkers. In this review, we provide an overview of the current understanding of IA pathology and highlight recent advances in biomarker research through multi‐omics approaches. We also propose strategies for integrating multi‐modal data to accelerate the development of molecular tools for the diagnosis, rupture prediction, prognosis, and personalized treatment of IA.